Synthesis, Biological Profile, and Quantitative Structure-Activity Relationship of a Series of Novel 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors

Journal of Medicinal Chemistry

Volumn 33, Issue 11, 1990, Pages 2982-2999

  Sit, S Y ^a   Parker, R A ^a   Motoc, I ^a   Han, W ^b   Balasubramanian, N ^b   Catt, J D ^b   Brown, P J ^b   Harte, W E ^b   Thompson, M D ^b   Wright, J J ^b  

^a Squibb Inst for Medical Research   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4,4 BIS(4 FLUOROPHENYL) 3 (1 METHYL 1H TETRAZOL 5 YL) 1,3 BUTADIENYL] 3,4,5,6 TETRAHYDRO 4 HYDROXY 2H PYRAN 2 ONE; 9,9 BIS(4 FLUOROPHENYL) 3,5 DIHYDROXY 8 (1 METHYL 1H TETRAZOL 5 YL) 6,8 NONADIENOIC ACID; 9,9 BIS(4 FLUOROPHENYL) 3,5 DIHYDROXY 8 (5 TETRAZOLYL) 6,8 NONADIENOIC ACID DERIVATIVE; BMY 21950; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; INFRARED SPECTROPHOTOMETRY; LIVER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTICHOLESTEREMIC AGENTS; BINDING, COMPETITIVE; BUTADIENES; CHEMISTRY; CHOLESTEROL; COMPARATIVE STUDY; FATTY ACIDS, UNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRONES; RATS; RATS, INBRED STRAINS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 0025000298     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00173a013     Document Type: Article

References (91)

1. Racemic material, the resolved (+)-enantiomer showed twice the activity as compared to the racemic compound.
2. Preliminary results of this paper were presented: Sit, S. Y.; Parker, R. A.; Brown, P. J.; Balasubramanian, N.; Catt, J. D.; Harte, W. E.; Motoc, I. I.; Wright, J. J. The 196th National Meeting of the American Chemical Society, Los Angeles, CA, September 26–30, 1988, MEDI 108.
3. Sit, S. Y.; Wright, J. J. Patent WO W08806584, issued on September 7, 1988.
4. Other analogues of BMY 21950: Brown, P. J.; Balasubramanian, N.; Catt, J. D.; Sit, S. Y.; Harte, W. E.; Parker, R. A.; Wright, J. J. The 197th National Meeting of the American Chemical Society, Dallas, TX, April 9-14, 1989, MEDI 16.
5. Balasubramanian, N.; Brown, P. J.; Catt, J. D.; Han, W. T.; Parker, R. A.; Sit, S. Y.; Wright, J. J. J. Med. Chem. 1989, 32, 2038.
6. Anderson, K. M.; Castelli, W. P.; Levy, D. JAMA, J. Am. Med. Assoc. 1987, 257 (16), 2176.
7. Steinberg, D. Circulation 1987, 76 (3), 502.
8. Havel, R. J. J. Clin. Invest. 1988, 81, 1653.
9. Endo, A. In Specific Nonsterol Inhibitors of HMG-CoA Reductase. Regulation of HMG-CoA Reductase-, Preiss, B., Ed.; Academic Press: New York, 1985; p 49.
10. Lee, T.-J. Trends Pharm. Sci. 1987, 8, 443 and references therein.
11. Stereospecific synthesis of the 3,5-dihydroxy side chain has been a subject of several publications, for example, Heathcock, C. H., Rosen, T. Tetrahedron 1986, 42 (18), 4909 and references therein.
12. Synthesis of 6 is described in Scheme I.
13. Hoffman, W. F.; Alberts, A. W.; Anderson, P. S.; Chen, J. S.; Smith, R. L.; Willard, A. K. J. Med. Chem. 1986, 29, 849.
14. Stokker, G. E.; Alberts, A. W.; Gilfillan, J. L.; Huff, J. W.; Smith, R. L. J. Med. Chem. 1986, 29, 852.
15. Stokker, G. E.; Alberts, A. W.; Anderson, P. S.; Cragoe, E. J., Jr.; Deana, A. A.; Gilfillan, J. L.; Hirshfield, J.; Holtz, W. J.; Hoffman, W. F.; Huff, J. W.; Lee, T. J.; Novello, F. C.; Prugh, J. D.; Rooney, C. S.; Smith, R. L.; Willard, A. K. J. Med. Chem. 1986, 29, 170.
16. Stokker, G. E.; Hoffman, W. F.; Alberts, A. W.; Cragoe, E. J., Jr.; Deana, A. A.; Gilfillan, J. L.; Huff, J. W.; Novello, F. C.; Prugh, J. D.; Smith, R. L.; Willard, A. K. J. Med. Chem. 1985, 28, 347.
17. Hoffman, W. F.; Alberts, A. W.; Cragoe, E. J., Jr.; Deana, A. A.; Evans, B. E.; Gilfillan, N. P.; Gould, J. L.; Huff, J. W.; Novello, F. C.; Prugh, J. D.; Rittle, K. E.; Smith, R. L.; Willard, A. K. J. Med. Chem. 1986, 29,159.
18. Kathawala, F. G. Patent WO 8402131, issued on June 7, 1984.
19. Wareing, J. R. Patent WO 8600307, issued on January 16, 1986.
20. Anderson, P. L. Patent WO 8402903, issued on August 2,1984.
21. Endo, A. J. Med. Chem. 1985, 28,401.
22. Boader, E.; Baitmann, W.; Beck, G.; Bergmann, A.; Jendialla, H.; Kessler, K.; Wess, G.; Schnbert, W.; Granzer, E.; Kerekjarto, B. V.; Krause, R. Tetrahedron Lett. 1988, 29 (8), 929.
23. Luijten, J. G. A.; Jassen, M. J.; van der Kerk, G. J. M. Recl. Trav. Chim. Pays-Bas 1962, 81, 202.
24. Singh, H.; Chawla, A. S.; Kapoor, V. K.; Paul, D.; Malhortra, R. K. Medicinal Chemistry of Tetrazoles. Prog. Med. Chem. 1980, 17, 151.
25. The regiochemical assignments were determined by an independent synthesis of one of the isomeric products (18a) from known starting materials; see Scheme III for a full description.
26. Sato, A.; Ogiso, A.; Noguchi, H.; Mitsui, S.; Kaneko, I.; Shi-mado, Y. Chem. Pharm. Bull. 1980, 28 (5), 1509.
27. Jones, G. Org. React. 1967, 15, 204.
28. Egawa, Y.; Srozuki, M.; Okuda, T. Chem. Pharm. Bull. 1963, 11, 589.
29. Prout, F. S. Organic Synthesis; Wiley: New York, 1963; Collect. Vol. 4, p 93.
30. Rate of condensation was observed to be slow and was further retarded if higher boiling solvents (such as toluene, xylenes, ethylbenzene) were used. Large excess of ethyl cyanoacetate could speed up the reaction, but a similar period of time was needed to achieve the stated yields.
31. The strongly electron deficient olefin 5 can also be cleaved by primary amines such as 2,2-dimethoxyethylamine to give the following imine.
32. Balasubramanian, N.; Brown, P. J.; Catt, J. D.; Han, W. T.; Sit, S. Y.; Wright, J. J. 196th National Meeting of the American Chemical Society, Los Angeles, CA, September 26–30, 1988. MEDI 109.
33. Narasaka, K.; Pai, F. C. Tetrahedron 1984, 40, 2233.
34. Kathawala, F. G.; Prager, B.; Prassad, K.; Repic, O.; Shapiro, M. J.; Stabler, R. S.; Widler, L. Helv. Chim. Acta 1986, 69, 803.
35. Chen, K.; Hartmann, G.; Prassed, K.; Repic, O.; Shapiro, M. J. Tetrahedron Lett. 1987, 155.
36. On a smaller scale, a cosolvent was added (such as toluene) and a longer heating period was also required to initiate the dipolar cycloaddition. The reaction was always carried out behind a safety shield although it was (uneventfully) repeated many times.
37. More steric hindered electrophiles such as 2-iodopropane gave more 2N-isomer. Isobutylene alkylation in ether gave a single 2N-tert-butyl tetrazole derivative.
38. The changes in the product ratio may be attributed to the intramolecular chelation of the countercation to the ester carbonyl group.
39. Howard, J.; Raap, R. Can. J. Chem. 1969, 47, 813.
40. 1,5-Dimethyltetrazole was once commercially available from Aldrich Chemicals and is still commercially available from Dynamite Nobel on a custom-order basis. Preparation: Condon, F. E.; Walfmann, R.; Kundu, N.; Trivedi, J. P. Org. Prep. Proc. 1974, 6 (3), 135.
41. The primary purpose of performing this experiment was to establish the regiochemistry of 18a and 18b. In practice, a single fractional crystallization of the methylation crude product could provide over 50% yield of the desired product 18a.
42. Campaigne, E.; Frierson, M. R. J. Heterocyclic Chem. 1979, 16, 235.
43. Product was contaminated by a small amount (2-4%) of 1-methyl-5-isopropyltetrazole arising from the bis-alkylation.
44. The versatile bromide 29 was also oxidized by 2-nitropropane (EtONa) to furnish over 95% of aldehyde 20a. This intermediate is useful for analogue synthesis.
45. In some cases, the phosphonate ester 30a anion did not couple cleanly to produce a single geometric isomer but a mixture of both (trans and cis); the corresponding triphenylphosphorane Wittig reagent was therefore prepared (details in the Experimental Section).
46. Jewell, C. F.; Wareing, J. R. (Sandoz) US Patent 4677211, issued on June 30, 1987.
47. The lithium carboxylate salt (generated by adding a molar equivalent of n-BuLi into the free acid) was used in the coupling with the anion of phosphonate ester.
48. Majewski, M.; Clive, D. L. J.; Anderson, P. Tetrahedron Lett. 1984, 25 (20), 2102.
49. Parker, R. A.; Miller, S. J.; Gibson, D. M. J. Biol. Chem. 1989, 264 (9), 4877.
50. Parker, R. A.; Miller, S. J.; Gibson, D. M. Biochem. Biophys. Res. Commun. 1984, 125, 629.
51. Shapiro, D. J.; Nordstrom, J. L.; Mitschelen, J. J.; Rodwell, V. W.; Schimke, R. T. Biochem. Biophys. Acta. 1974, 370, 369.
52. Ingebritsen, T. S.; Gibson, D. M. Methods Enzymol. 1981, 71, 486.
53. Seglen, P. O. Preparation of isolated rat liver cells. Methods Cell Biol. 1976, 13, 29.
54. Ingebritsen, T. S.; Geelen, M. J. H.; Parker, R. A.; Evenson, K. J.; Givson, D. M. J. Biol. Chem. 1979, 254, 9986.
55. Kates, M. Techniques of lipidology, isolation, analysis and identification. In Identification of Lipids, Kates, M., Ed.; American Elsevier: New York, 1972; p 349.
56. Tsujita, Y.; Kuroda, M.; Shimada, Y. Biochim. Biophys. Acta 1986, 877, 50.
57. Moriwaki, K.; Gomi, M.; Itoh, Y. Life Sci. 1986, 38, 453.
58. Spady, D. K.; Dietschy, J. M. J. Lipid Res. 1983, 24, 303.
59. Stange, E. F.; Dietschy, J. M. Sterols and bile acids. In New Comprehensive Biochemistry; Danielson, H., Sjovall, J., Ed.; Elsevier: New York, 1985; Vol. 12, p 121.
60. Alberts, A. W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; Patchett, A.; Monaghan, R.; Currie, S.; Stapley, E.; Albers-Schonberg, G.; Hensens, O.; Hirshfield, J.; Hoogsteen, K.; Liesch, J.; Springer, J. Proc. Natl. Acad. Sci. U.SA. 1980, 77, 3957.
61. Hitchener, W. R.; Cenedella, R. J. J. Lipid Res. 1985, 26, 1455.
62. Goto, Y. Drugs affecting lipid metabolism. In Proceedings in Life Sciences; Paoletti, R., Ed.; Springer-Verlag: New York, 1987; p 247
63. Germershausen, J. I.; Hunt, V. M.; Bostedor, R. G.; Bailey, P. J.; Karkas, J. D.; Alberts, A, W.; Biochem. Biophys. Res. Commun. 1989, 158, 667.
64. Slater, E. E.; MacDonald, J. S. Drugs 1988, 36 (Suppl. 3), 72.
65. Parker, R. A.; Sit, S. Y.; Wright, J. J.; Clark, R. W.; Grosso, R. A.; Keely, S. L.; Antonaccio, M. J. Arteriosclerosis 8, 634a.
66. Parker, R. A.; Sit, S. Y.; Clark, R. W.; Grosso, R. A.; Wright, J. J.; Keely, S. L. FASEB J. 3, A644.
67. Clark, R. W.; Grosso, R. A.; Parker, R. A. FASEB J. 3, A953.
68. Only the primary amino acid sequences for human and hamster HMG-CoA reductase are known: Luskey, K. L.; Steven, B. J. Biol. Chem. 1985, 260, 10271.
69. Being less relevant in the present context, these results are not reported here.
70. 50value reported for this compound was not in agreement with ours. In order that we could conform to the experimental uniformity, we therefore employed our data despite the discrepancy.
71. Marshall, G. R.; Barry, C. D.; Bossard, H. E.; Dammkoehler, R. A. ACS Symp. Ser. 1979, 112, 205.
72. Motoc, I.; Dammkoehler, R. A.; Mayer, D.; Labanowski, J. Quant. Struct.-Act. Relat. 1986, 5, 138.
73. Mayer, D.; Naylor, C. B.; Motoc, I.; Marshall, G. R. J. Comput.-Aided Mol. Design 1987, 1, 3.
74. Sybyl Molecular Modeling Software, Tripos Assoc./Evans & Sutherland, St. Lous, MO.
75. Labanowski, J.; Motoc, I.; Naylor, C. B.; Mayer, D.; Dammkoehler, E. A. Quant. Struct.-Act. Relat. 1986, 5, 138.
76. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology; Wiley: New York, 1979.
77. Balaban, A. T.; Chiriac, A.; Motoc, I.; Simon, Z. Steric Fit in Quantitative Structure-Activity Relations; Springer: Berlin, 1980.
78. Motoc, I. Quant. Struct.-Act. Relat. 1984, 3, 43, 47.
79. Motoc, I.; Marshall, G. R.; Labanowski, J. Z. Naturforsch. 1985, 40a, 1121.
80. Motoc, I.; Marshall, G. R.; Dammkoehler, R. A.; Labanowski, J. Naturforsch. 1985, 40a, 1108.
81. Balaban, A. T.; Chiriac, A.; Motoc, I.; Simon, Z. Steric Fit in Quantitative Structure-Activity Relations; Springer: Berlin, 1980.
82. Motoc, I. Arzneim.-Forsch., Drug Res. 1981, 31, 290.
83. Hopfinger, A. J. J. Am. Chem. Soc. 1980, 102, 7196.
84. For recent reviews: Marshall, G. R.; Motoc, I. In Molecular Graphics and Drug Design; Burgen, A. S. V., Roberts, G. C. K., Tute, M. S., Eds.; Elsevier: Amsterdam, 1986; Chapter 5.
85. Mabilia, M.; Pearlstein, R. A.; Hopfinger, A. J. Molecular Graphics and Drug Design Chapter 6.
86. The values of the atomic van der Waals radius (rw, Å) used in calculations are: 1.08 (H), 1.53 (C), 1.48 (N), 1.65 (Cl), 1.30 (F), 1.75 (P), 1.72 (S).
87. Draper, N.; Smith, H. Applied Regression Analysis, Wiley: New York, 1981.
88. For previous use of cross-validation in regression models, see: Cramer, R. D.; Patterson, D. E.; Bunce, F. D. J. Am. Chem. Soc. 1988, 110, 5959.
89. Levine, I. N. Quantum Chemistry, 3rd ed.; Allyn and Bacon: Boston, 1986; p 481.
90. Baader, E.; Bartman, W.; Bergmann, A.; Lendralla, H.; Kes-seller, K.; Wess, G.; Schubert, W. Actual. Chim. Ther. 1989, 16, 133.
91. Hopfinger54 has utilized the overlapping volume descriptor, S0, and its square, S02, in molecular shape analysis studies in combination with other parameters (e.g., partition coefficients, length of substituent) and has further utilized the conformation corresponding to one of the energy minima of a selected compound of the series under consideration as reference structure.